vs

Side-by-side financial comparison of Linde plc (LIN) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.

Linde plc is the larger business by last-quarter revenue ($8.8M vs $7.0M, roughly 1.3× Relay Therapeutics, Inc.). Linde plc produced more free cash flow last quarter ($898.0K vs $-235.9M).

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.

LIN vs RLAY — Head-to-Head

Bigger by revenue
LIN
LIN
1.3× larger
LIN
$8.8M
$7.0M
RLAY
More free cash flow
LIN
LIN
$236.8M more FCF
LIN
$898.0K
$-235.9M
RLAY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LIN
LIN
RLAY
RLAY
Revenue
$8.8M
$7.0M
Net Profit
Gross Margin
48.5%
Operating Margin
27.8%
Net Margin
Revenue YoY
8.2%
Net Profit YoY
EPS (diluted)
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIN
LIN
RLAY
RLAY
Q1 26
$8.8M
Q4 25
$8.8B
$7.0M
Q3 25
$8.6B
$0
Q2 25
$8.5B
Q1 25
$8.1B
$7.7M
Q4 24
$8.3B
$0
Q3 24
$8.4B
$0
Q2 24
$8.3B
$0
Net Profit
LIN
LIN
RLAY
RLAY
Q1 26
Q4 25
$1.5B
Q3 25
$1.9B
$-74.1M
Q2 25
$1.8B
Q1 25
$1.7B
$-77.1M
Q4 24
$1.7B
Q3 24
$1.6B
$-88.1M
Q2 24
$1.7B
$-92.2M
Gross Margin
LIN
LIN
RLAY
RLAY
Q1 26
48.5%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Operating Margin
LIN
LIN
RLAY
RLAY
Q1 26
27.8%
Q4 25
23.0%
Q3 25
27.5%
Q2 25
27.7%
Q1 25
26.9%
-1105.2%
Q4 24
27.4%
Q3 24
25.0%
Q2 24
26.4%
Net Margin
LIN
LIN
RLAY
RLAY
Q1 26
Q4 25
17.5%
Q3 25
22.4%
Q2 25
20.8%
Q1 25
20.6%
-1003.6%
Q4 24
20.8%
Q3 24
18.5%
Q2 24
20.1%
EPS (diluted)
LIN
LIN
RLAY
RLAY
Q1 26
$3.98
Q4 25
$3.28
Q3 25
$4.09
$-0.43
Q2 25
$3.73
Q1 25
$3.51
$-0.46
Q4 24
$3.61
Q3 24
$3.22
$-0.63
Q2 24
$3.44
$-0.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIN
LIN
RLAY
RLAY
Cash + ST InvestmentsLiquidity on hand
$4.0M
$84.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$40.1M
$567.1M
Total Assets
$86.3M
$621.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIN
LIN
RLAY
RLAY
Q1 26
$4.0M
Q4 25
$5.1B
$84.0M
Q3 25
$4.5B
$91.6M
Q2 25
$4.8B
Q1 25
$5.3B
$93.5M
Q4 24
$4.8B
$124.3M
Q3 24
$5.2B
$152.4M
Q2 24
$4.6B
$134.1M
Total Debt
LIN
LIN
RLAY
RLAY
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
LIN
LIN
RLAY
RLAY
Q1 26
$40.1M
Q4 25
$38.2B
$567.1M
Q3 25
$38.6B
$607.7M
Q2 25
$38.5B
Q1 25
$38.0B
$721.1M
Q4 24
$38.1B
$777.8M
Q3 24
$39.2B
$838.9M
Q2 24
$38.2B
$681.7M
Total Assets
LIN
LIN
RLAY
RLAY
Q1 26
$86.3M
Q4 25
$86.8B
$621.3M
Q3 25
$86.0B
$670.0M
Q2 25
$86.1B
Q1 25
$82.7B
$799.4M
Q4 24
$80.1B
$871.3M
Q3 24
$82.5B
$930.1M
Q2 24
$80.2B
$772.5M
Debt / Equity
LIN
LIN
RLAY
RLAY
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIN
LIN
RLAY
RLAY
Operating Cash FlowLast quarter
$-235.5M
Free Cash FlowOCF − Capex
$898.0K
$-235.9M
FCF MarginFCF / Revenue
10.2%
-3370.0%
Capex IntensityCapex / Revenue
5.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B
$-622.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIN
LIN
RLAY
RLAY
Q1 26
Q4 25
$3.0B
$-235.5M
Q3 25
$2.9B
$-62.1M
Q2 25
$2.2B
Q1 25
$2.2B
$-73.2M
Q4 24
$2.8B
$-249.1M
Q3 24
$2.7B
$-75.1M
Q2 24
$1.9B
$-65.8M
Free Cash Flow
LIN
LIN
RLAY
RLAY
Q1 26
$898.0K
Q4 25
$1.6B
$-235.9M
Q3 25
$1.7B
$-62.1M
Q2 25
$954.0M
Q1 25
$891.0M
$-73.6M
Q4 24
$1.6B
$-251.1M
Q3 24
$1.7B
$-75.3M
Q2 24
$796.0M
$-65.8M
FCF Margin
LIN
LIN
RLAY
RLAY
Q1 26
10.2%
Q4 25
17.9%
-3370.0%
Q3 25
19.4%
Q2 25
11.2%
Q1 25
11.0%
-958.4%
Q4 24
18.8%
Q3 24
19.9%
Q2 24
9.6%
Capex Intensity
LIN
LIN
RLAY
RLAY
Q1 26
Q4 25
16.6%
5.9%
Q3 25
14.8%
Q2 25
14.8%
Q1 25
15.7%
5.0%
Q4 24
15.1%
Q3 24
12.8%
Q2 24
13.7%
Cash Conversion
LIN
LIN
RLAY
RLAY
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons